Becaplermin - Biologic Drug Details

Summary for becaplermin

Tradenames:	1
Patents:	1
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for becaplermin

Recent Clinical Trials for becaplermin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Adocia	Phase 1/Phase 2
Virchow Group	Phase 1/Phase 2
Bedford Research Corporation, Inc.

See all becaplermin clinical trials

Pharmacology for becaplermin

Established Pharmacologic Class	Human Platelet-derived Growth Factor
Chemical Structure	Platelet-Derived Growth Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for becaplermin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for becaplermin Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691		2012-10-10	Company disclosures

3) Low Certainty: US Patents for becaplermin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691		2032-02-15	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691		2034-12-01	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691		2033-05-17	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691		2025-04-05	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691		2035-03-11	Patent claims search

International Patents for becaplermin

Country	Patent Number	Estimated Expiration
Canada	2234235
South Africa	968398
Germany	69617723
South Korea	890004720
World Intellectual Property Organization (WIPO)	9712601

Supplementary Protection Certificates for becaplermin

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SZ 36/1999	Austria		PRODUCT NAME: BECAPLERMIN
C990016	Netherlands		PRODUCT NAME: BECAPLERMINUM; REGISTRATION NO/DATE: EU/1/99/101/001 19990329
SPC/GB99/023	United Kingdom		PRODUCT NAME: BECAPLERMIN; REGISTERED: UK EU/1/99/101/001 19990329
99C0034	Belgium		PRODUCT NAME: BECAPLERMIN; REGISTRATION NO/DATE: EU/1/99/101/001 19990329